Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | NYSE

Overview

Corporate Details

ISIN(s):: US48301N1046
LEI:
Country:: United States of America
Address:: 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Website:: https://kairospharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Biosergen AB Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.	Sweden	BIOSGN
Bio Solution Co.,Ltd. Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.	South Korea	086820
Biosynex European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.	France	ALBIO
BIO-TECHNE Corp Develops reagents and instruments for life sciences research and clinical diagnostic markets.	United States of America	TECH
biote Corp. Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.	United States of America	BTMD
Biotest AG Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.	Germany	BIO3
Biotika A.S. Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.	Slovakia	BSL
Bioton S.A. Develops and manufactures recombinant human insulin for global diabetes care solutions.	Poland	BIO
BIOVENTIX PLC Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.	United Kingdom	BVXP
Bioversys N Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.	Switzerland	BIOV